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Abstract
Background: To date, standardized strategies for the treatment of recurrent glioma are lacking. Chemotherapy with
the alkylating agent BCNU (1,3-bis (2-chloroethyl)-1-nitroso-urea) is a therapeutic option even though its efficacy
and safety, particularly the risk of pulmonary fibrosis, remains controversial. To address these issues, we performed a
retrospective analysis on clinical outcome and side effects of BCNU-based chemotherapy in recurrent glioma.
Methods: Survival data of 34 mostly chemotherapy-naïve glioblastoma patients treated with BCNU at 1st relapse
were compared to 29 untreated control patients, employing a multiple Cox regression model which considered
known prognostic factors including MGMT promoter hypermethylation. Additionally, medical records of 163 patients
treated with BCNU for recurrent glioma WHO grade II to IV were retrospectively evaluated for BCNU-related side effects
classified according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 2.0.
Results: In recurrent glioblastoma, multiple regression survival analysis revealed a significant benefit of BCNU-based
chemotherapy on survival after relapse (p = 0.02; HR = 0.48; 95 % CI = 0.26–0.89) independent of known clinical and
molecular prognostic factors. Exploratory analyses suggested that survival benefit was most pronounced in MGMT-
hypermethylated, BCNU-treated patients. Moreover, BCNU was well tolerated by 46 % of the 163 patients analyzed for
side effects; otherwise, predominantly mild side effects occurred (CTCAE I/II; 45 %). Severe side effects CTCAE III/IV were
observed in 9 % of patients including severe hematotoxicity, thromboembolism, intracranial hemorrhage and injection
site reaction requiring surgical intervention. One patient presented with a clinically apparent pulmonary fibrosis CTCAE
IV requiring temporary mechanical ventilation.
Conclusion: In this study, BCNU was rarely associated with severe side effects, particularly pulmonary toxicity, and, in
case of recurrent glioblastoma, even conferred a favorable outcome. Therefore BCNU appears to be an appropriate
alternative to other nitrosoureas although the efficacy against newer drugs needs further evaluation.
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Background
In newly diagnosed glioblastoma (GBM) World Health
Organization (WHO) grade IV, maximum safe tumor re-
section followed by radio-chemotherapy with the alkylat-
ing agent temozolomide (TMZ) has been shown to be
the most effective treatment and hence has evolved as
standard therapy [1, 2]. At tumor recurrence, however,
no standard of care has been defined so far. Therapeutic
options have to be weighed carefully with regard to
tumor size and location, clinical presentation and pre-
treatment. Re-resection should be considered where ap-
propriate; however, evidence of a favorable outcome is still
poor due to heterogeneously pre-treated patients and
many studies lacking standardized postoperative imaging
[3–6]. Similarly, there are still a limited number of studies
addressing re-irradiation for recurrent GBM [7–10].
Systemic chemotherapy is probably the most widely
used salvage therapy for recurrent GBM though only a
modest survival benefit has been demonstrated [11–17].
The interest in well-tolerated treatment regimens has
grown due to a rising number of glioma patients pre-
treated with TMZ, resulting in a reduced bone marrow
reserve that may influence the efficacy and tolerance of
additional chemotherapy. Nitrosourea derivatives, an-
other class of alkylating agents, are widely applied in
recurrent glioma even though their value remains con-
troversial. In patients pre-treated with TMZ, there are
few data available regarding the efficacy and tolerance of
nitrosourea-based chemotherapy. Recent data demon-
strated that the nitrosourea derivative ACNU alone
failed to stabilize the disease in recurrent GBM [18]
whereas ACNU in combination with teniposide (VM26)
has been shown to be moderately effective in these pa-
tients but at the expense of an increased high-grade
hematotoxicity [19]. For CCNU, another nitrosourea de-
rivative, efficacy and safety was demonstrated both in
newly diagnosed [20, 21] and recurrent [22] high-grade
glioma. In North America the nitrosourea derivate
BCNU (1,3-bis (2-chloroethyl)-1-nitroso-urea) historic-
ally has been applied more extensively both at initial
diagnosis and at tumor recurrence than other nitro-
sourea derivatives. In Europe, BCNU lately experienced
a renaissance after approval of ACNU has expired. As
second-line chemotherapy, BCNU has been tested alone
or in combination, among others with TMZ, irinotecan,
cisplatin and thalidomide [23–27]. In a phase II trial
conducted by Brandes et al. treating chemotherapy-naïve
patients with recurrent GBM, BCNU-based chemother-
apy was the only independent prognostic factor for a
prolonged progression-free survival at 6 months (PFS-6)
after onset of chemotherapy (17.5 %), however at the ex-
pense of long lasting hepatic and pulmonary toxicity
[23]. In TMZ-pre-treated patients with recurrent GBM,
BCNU in combination with irinotecan displayed a PFS-6
of 30.3 % with manageable toxicity [24]. In a recent
retrospective analysis of 35 TMZ-pre-treated patients
with recurrent GBM, a median PFS-6 of 13 %, a PFS of
11 weeks and an overall survival (OS) of 22 weeks after
BCNU treatment were reported [28]. Common side ef-
fects of BCNU-based chemotherapy include nausea/
vomiting and hematotoxicity with a delayed nadir after
4-6 weeks. The most dreaded side effect, however, is pul-
monary fibrosis, leaving the preference of BCNU over
other cytotoxic drugs controversial. Since data on
BCNU-related side effects and its impact on patient out-
come are still sparse and interpretation of study results
is often hindered by a heterogeneously pre-treated pa-
tient sample, further evaluation of safety and efficacy in
a large and homogeneously pre-treated cohort is war-
ranted in order to consider BCNU as an appropriate
treatment alternative.
To address these issues, we performed a retrospective
analysis of 163 predominantly chemotherapy-naïve pa-
tients treated with BCNU for recurrent glioma WHO
grade II to IV at the Department of Neurosurgery, Uni-
versity Hospital Heidelberg. Side effects were classified
according to the National Cancer Institute Common
Toxicity Criteria for Adverse Events (CTCAE) with spe-
cial attention paid to pulmonary toxicity. In addition,
clinical outcome was analyzed in 63 GBM patients with or
without BCNU-based chemotherapy at tumor recurrence,
adjusted for potential clinical (age, extent of resection
(EOR) at 1st surgery, TMZ at 1st diagnosis, treatment in-
tensity at tumor recurrence) and molecular MGMT (O6-
methylguanine DNA methyltransferase) promoter hyper-
methylation) prognostic factors. Only IDH (isocitrate
dehydrogenase) wildtype patients entered survival ana-
lysis, taking into account the unique molecular and prog-
nostic phenotype associated with IDH mutations [29].
Methods
Patient sample
Medical records of glioma patients treated at the Depart-
ment of Neurosurgery, University Hospital Heidelberg,
were screened for demographic data (age, gender), Kar-
nofsky Performance Scale score (KPS), histology, treat-
ment regimens (e.g. surgery, radiotherapy, chemotherapy),
and survival data. Information was collected in a Micro-
soft Access™ database. Written informed consent was ob-
tained from each patient according to the research
proposals approved by the Institutional Review Board at
Heidelberg Medical Faculty.
Side effects
One hundred sixty-three patients were identified from
this database having received BCNU-based chemother-
apy for recurrent glioma WHO grade II to IV between
1995 and 2005. Medical records were screened for
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chemotherapy-related side effects that were classified ac-
cording to the CTCAE version 2.0. Our in-house proto-
col included the intravenous administration of freshly
prepared BCNU at 100 mg/m2 daily on two consecutive
days every 6 - 8 weeks. Patients were followed by blood
tests every other week as well as chest X-rays for the de-
velopment of pulmonary fibrosis and MRI scans for
tumor response every 3 months. Dose reduction was
performed at the physician’s discretion when patients
presented with severe hematotoxicity, renal dysfunction
or a poor physical condition. Efficacy of BCNU-based
chemotherapy was determined for each WHO grade
employing the Kaplan-Meier method. Progression-free
survival after BCNU (PFSBCNU) was defined as the time
interval between onset of BCNU treatment and change
of treatment or death, whatever occurred first, and over-
all survival (OS) was defined as the time interval be-
tween histological diagnosis and death. Subjects were
censored to survival analysis if the corresponding event
(PFSBCNU: change of treatment after BCNU-based
chemotherapy/death; OS: death) was not observed dur-
ing follow-up (until April 2015).
Outcome
For in-depth univariate and multiple survival analyses
addressing the efficacy of BCNU-based chemotherapy in
recurrent GBM, 135 patients with recurrent GBM
treated at our institution between 1995 and 2005 were
identified from our database. 72 patients were excluded
due to insufficient documentation, missing follow-up in-
formation, presence of IDH mutation or lack of tissue
samples to determine MGMT promoter methylation sta-
tus. The remaining 34 cases with (BCNU group) and 29
cases without (control group) BCNU treatment at 1st
tumor relapse entered survival analyses. A patient was
considered to have recurrent disease if this was revealed
either by MRI or neurological deterioration, leading to
an adaption of anti-tumor therapy. Hence, PFS was de-
fined as the time interval between histological diagnosis
and tumor recurrence and survival after relapse as the
time interval between tumor recurrence and death. All
patients died during follow up. Estimated hazard ratios
were adjusted for established prognostic factors (patient’s
age at diagnosis, KPS at tumor recurrence, EOR at 1st
surgery, TMZ at 1st diagnosis) and other potential con-
founders (therapies other than BCNU at tumor recur-
rence). In all cases, the EOR was determined by MRI
scans taken within 72 h after surgery, and complete re-
section (CR) was defined as no residual contrast-
enhancing tumor. Furthermore, MGMT promoter
hypermethylation, a molecular marker predictive of the
treatment response to alkylating agents like nitrosoureas
and temozolomide [30, 31], was also included in the
multiple regression analysis.
Molecular markers
IDH1 R132H mutation was ruled out by immunohisto-
chemistry as previously described [32]. Due to the re-
ported low frequency of IDH mutations in primary
glioblastomas, cases negative for IDH1 R132H immuno-
histochemistry were designated as IDH wildtype. For
confirmation, we performed direct sequencing of the
mutation hotspot regions of IDH1 (n = 23) and IDH2 (n
= 10) for selected cases as described [33]. As expected,
no rare IDH1 or IDH2 mutations were detected by se-
quencing among these cases. MGMT promoter methyla-
tion status was determined by methylation-specific
polymerase chain reaction as previously described [34].
Statistical analysis
Statistical evaluation of BCNU-related side effects was
performed employing Microsoft Excel™ software. Univar-
iate survival analysis was based on the Kaplan-Meier
method and multiple survival analyses relied on propor-
tional hazard regression models, where BCNU and other
therapies after relapse were treated as time-dependent
variables. Statistical analyses were conducted using SAS
version 9.2 and Kaplan-Meier curves were plotted using
R version 2.11.1 (The R Project for Statistical Comput-
ing, http://www.r-project.org/). Group differences were
assessed with the nonparametric Mann–Whitney test for
continuous variables and with Fisher’s exact and Chi-
square tests for ordinal scaled variables using Graph-Pad
Prism software (Version 5.0c, Graph Pad Inc., CA, USA).
P-values ≤ 0.05 were considered statistically significant.
Results
Analysis of BCNU-related side effects
No standard of care exists for recurrent glioma, but
nitrosourea derivatives, among others BCNU, are con-
sidered appropriate options. We identified 163 patients
from our database treated with BCNU for recurrent gli-
oma WHO grade II to IV and retrospectively evaluated
their medical histories in view of possible BCNU-related
side effects. Median age at the onset of BNU-based
chemotherapy was 44 years (range 17–81 years) with a
male preponderance of 2:1. Median KPS (defined as low-
est KPS observed during the treatment period) was
80 %. Apart from BCNU, 147 patients (90 %) received ir-
radiation and 20 (12.2 %), 4 (2.4 %) and 2 (1.2 %) patients
TMZ, PCV (procarbazine, CCNU, vincristine) and metho-
trexate, respectively (Table 1). BCNU was administered in
a median total dose of 1662 mg (range 300–5200 mg) dur-
ing a median number of 5 cycles (range 1–16 cycles). Dose
reduction was necessary in 48 patients (29.4 %) due to
hematotoxicity, renal dysfunction or a poor physical con-
dition (Table 1). Most patients received BCNU for recur-
rent high-grade glioma WHO grade IV (51.5 %) and III
(35 %), in the latter preferably with an oligodendroglial
Jungk et al. BMC Cancer  (2016) 16:81 Page 3 of 11
component (oligodendroglioma (18.4 %) and mixed gli-
oma (8.6 %) WHO grade III) (Table 1).
Eighty-eight of 163 patients (54 %) experienced
BCNU-related side effects (Fig. 1). The frequency of side
effects was not equally distributed among tumor grades,
with WHO grade IV patients experiencing least (42 %)
and WHO grade II patients experiencing most fre-
quently (82 %) side effects (Table 1). In general, BCNU
was well tolerated since mainly mild side effects CTCAE
I/II (45 % of all patients) occurred, predominantly due to
myelosuppression (48 % of all patients with side effects;
Fig. 1) resulting in leucopenia (33 %), thrombocytopenia
(24 %) or anemia (9.6 %). Otherwise CTCAE I/II side ef-
fects consisted of nausea/vomiting, fatigue, obstipation/
diarrhea and injection site reaction. Severe side effects
CTCAE III/IV were rarely observed (9 % of all patients)
including myelosuppression (6 %), thromboembolism
(one patient with a deep venous thrombosis and pul-
monary embolism each; 1.2 %), intracranial hemorrhage
due to a chronic subdural hematoma (0.6 %), and injec-
tion site reaction requiring surgical intervention (0.6 %)
(Table 2). One out of 163 patients (0.6 %) presented with
a clinically apparent pulmonary fibrosis CTCAE IV re-
quiring temporary mechanical ventilation, otherwise
routine chest X-rays and clinical examination revealed
no signs of pulmonary fibrosis (Fig. 1). Side effects clas-
sified as “others” were reported in timely correlation to
the administration of BCNU but were not explicitly re-
lated to it (Table 2). Hospital admission due to BCNU-
related side effects was necessary in 2 patients (1.2 %)
(Table 1). There were no BCNU-related deaths (Table 1).
Favorable outcome of patients treated with BCNU for
recurrent glioblastoma
Efficacy data of all patients analyzed for BCNU-related
side effects are listed in Table 1. PFSBCNU was 85, 28 and
7 months for WHO grade II, III and IV gliomas, respect-
ively. However, clinical courses and treatment plans were
very heterogeneous and outcome-related molecular
markers were available for a minority of patients only.
We therefore decided to focus on the impact of BCNU-
based chemotherapy on patient outcome in recurrent
GBM and analyzed a well-defined, homogeneously pre-
treated, mostly chemotherapy-naïve sample of 63 pa-
tients both by univariate and multiple survival regression
models. At initial diagnosis, all patients were pre-treated
with maximum safe tumor resection followed by irradi-
ation. At 1st relapse, patients underwent surgery where
appropriate followed by administration of BCNU (BCNU
group; n = 34 patients) or not (control group; n = 29
patients). All but 5 patients in each group were
chemotherapy-naïve by the time of tumor recurrence;
these patients received TMZ at initial diagnosis. Salvage
therapies at relapse apart from BCNU included (BCNU
Table 1 Baseline characteristics and efficacy data of patient
cohort analyzed for BCNU-related side effects
Patient Characteristics
Patient Sample [n] 163
Age at onset of BCNU therapy [years] (median; range) 44 (17–81)
Sex [male:female; n] 108:55
Karnofsky Performance Score [%] (median; range) 80 (20–100)
Histology [number of patients] (%)
Glioblastoma WHO grade IV 84 (51,5)
Oligodendroglioma WHO grade III 30 (18,4)
Oligoastrocytoma WHO grade III 14 (8,6)
Astrocytoma WHO grade III 13 (8)
Oligodendroglioma WHO grade II 12 (7,4)
Oligoastrocytoma WHO grade II 3 (1,8)
Astrocytoma WHO grade II 7 (4,3)
Median OS [months]
WHO grade II tumors 191
WHO grade III tumors 144
WHO grade IV tumors 20
Median PFSBCNU [months]
WHO grade II tumors 85
WHO grade III tumors 28
WHO grade IV tumors 7
Death [number of patients] (%)
WHO grade II tumors 9 (41)
WHO grade III tumors 37 (65)
WHO grade IV tumors 82 (98)
Lost to follow up [number of patients] (%)
WHO grade II tumors 5 (23)
WHO grade III tumors 13 (23)
WHO grade IV tumors 1 (1)
Pre-treatment [number of patients] (%)
Radiotherapy 147 (90)
Temozolomide 20 (12,2)
PCV 4 (2,4)
Methotrexate 2 (1,2)
BCNU – total dose [mg] (median; range) 1662 (300–5200)
BCNU – number of cycles (median; range) 5 (1–16)
BCNU-related side effects [number of patients] (%) 88 (54)
WHO grade II tumors 18 (82)
WHO grade III tumors 35 (61)
WHO grade IV tumors 35 (42)
BCNU – dose reduction to due side effects (%) 48 (29,4)
BCNU – Hospital admission due to side effects (%) 2 (1,2)
Chemotherapy-related deaths (%) 0
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group/control group; n): re-resection (9/1), re-irradiation
(4/5), TMZ (4/1), thalidomide (1/0) and CCNU (1/0).
Thus, treatment intensity at relapse was higher in the
BCNU group than in the control group (38.2 % versus
24.1 %; p = 0.28, Fisher’s exact test) and therefore was
included as a potential time-dependent confounder in
multiple survival analysis. Since re-irradiation and
chemotherapy were not necessarily considered thera-
peutic options for recurrent GBM during the time our
patients were treated and particularly TMZ was not
available outside clinical trials, BCNU was offered based
on individual decisions with risks and benefits carefully
weighed against each other, often at the patient’s request.
88.2 % of patients received ≤ 6 cycles of BCNU, 2 pa-
tients received more than 6 cycles and in 2 patients the
exact cycle number was not reliably determinable. Me-
dian age was 56 years for BCNU patients and 62 years
for control patients (p = 0.06; Mann–Whitney test). Me-
dian KPS at tumor recurrence was 80 % in the BCNU
group and 60 % in the control group based on patients
with available KPS information; however, due to the
retrospective study design reliable KPS information
could not be determined for all patients and was not
considered in multiple regression analyses. Frequency of
CR at 1st diagnosis was similar in both groups (BCNU:
32 %; control: 31 %); otherwise, surgical procedures con-
sisted of biopsy or subtotal resection (Table 3).
PFS was comparable in both groups (BCNU: median
186 days; control group: median 180 days; p = 0.78, Log-
rank test). However, BCNU-based chemotherapy con-
ferred a significant impact on survival after relapse
(BCNU: median 266 days; control group: median
187 days; p = 0.02, Log-rank test; Fig. 2a). In order to
take into account clinical (age at 1st diagnosis, EOR at
1st surgery, TMZ at 1st diagnosis, therapies other than
BCNU at tumor recurrence) and molecular (MGMT
promoter methylation) prognostic factors as potential
confounders, a multiple Cox proportional hazard ana-
lysis was performed. Results confirmed BCNU treatment
as independent prognostic factor for prolonged survival
after relapse (p = 0.02; HR = 0.48; 95 % CI = 0.26–0.89;
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Fig. 1 BCNU-related side effects as observed in 163 patients treated for recurrent glioma WHO II – IV. Side effects were classified according to the
CTCAE version 2.0 and are plotted on the x-axis
Table 2 Side effects of BCNU-based chemotherapy classified
according to CTCAE v.2.0
Side Effects (%) CTCAE I CTCAE II CTCAE III CTCAE IV
Patients with side effects 51 (31) 23 (14) 8 (5) 7 (4)
Leukopenia 38 (22,8) 17 (10,2) 2 (1,2) 1 (0,6)
Thrombocytopenia 35 (21) 5 (3) 5 (3) 1 (0,6)
Anemia 16 (9,6) - 1 (0,6) -
Nausea/Vomitus 3 (1,8) 2 (1,2) - -
Fatigue 1 (0,6) - - -
Obstipation/Diarrhea 2 (1,2) - - -
Pulmonary Fibrosis - - - 1 (0,6)
Thromboembolism - - 1 (0,6) 1 (0,6)
Hemorrhage - - - 1 (0,6)
Injection Site Reaction 1 (0,6) 2 (1,2) 1 (0,6) -
Othersa 4 (2,4) 2 (1,2) 2 (1,2) 1 (0,6)
aSide effects classified as “others” were found in timely but not necessarily
causal relation to BCNU administration and consisted of weight loss/loss of
appetite CTCAE I (1.2 %), arterial hypotension CTCAE I (0.6 %), neuropathic
pain CTCAE I (0.6 %), newly observed cranial nerve deficit CTCAE II (0.6 %),
photophobia CTCAE II (0.6 %) and hallucinations CTCAE III (0.6 %), anaphylaxis
CTCAE III (0.6 %) and isolated elevation of liver transaminases CTCAE IV (0.6 %)
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Table 4). Age at 1st diagnosis (p = 0.04; HR = 1.03; 95 %
CI = 1.00–1.05; Table 4) and TMZ at 1st diagnosis (p =
0.005; HR = 0.32; 95 % CI = 0.15–50.7; Table 4) simultan-
eously showed a significant impact on survival after re-
lapse. We also found some independent evidence on a
prolonged survival after relapse of patients treated with
other therapies than BCNU (p = 0.06; HR = 0.56; 95 %
CI = 0.30–1.02). In univariate exploratory analyses, sur-
vival after relapse differed in BCNU and control patients
with and without (w/o) additional therapies at relapse
(BCNU | with: 413 days; control | with: 290 days; BCNU
| w/o: 251 days; control | w/o: 181 days; Fig. 2b).
Notably, exploratory analysis revealed that the effect of
BCNU on survival after relapse was most pronounced
for MGMT-hypermethylated patients (n = 38; p = 0.007;
Fig. 2c). In patients with non-methylated MGMT pro-
moters (n = 25), no significant difference in survival after
relapse by BCNU treatment was observed (p = 0.68;
Fig. 2d).
Discussion
In this study, chemotherapy with the nitrosourea deriv-
ate BCNU for the treatment of recurrent glioma was
both effective and well tolerated. In a homogeneously
pre-treated, mostly chemotherapy-naïve sample of 63
patients suffering from recurrent IDH wildtype GBM,
outcome analysis revealed a survival benefit for patients
treated with BCNU at 1st tumor relapse since survival
after relapse was significantly prolonged compared to
control patients (BCNU: 266 days; control: 187 days; p =
0.02). This survival benefit was most pronounced for
MGMT-hypermethylated, BCNU-treated patients (p =
0.007). Even though median age, a known prognostic
factor for a favorable outcome [35, 36], was lower
(56 years versus 62 years; p = 0.06) and treatment inten-
sity at tumor recurrence was higher (38 % versus 24 %
Table 3 Description of patient cohort included in survival
analysis (n = 63 patients)
BCNU Control
Patient sample (n) 34 29
Age at 1st diagnosis (median; range) 56 (22–76) 62 (33–78)
Sex (male: female; n) 20:14 16:13
KPS (median; range) 8 (4–10) 6 (3–9)
MGMT promoter hypermethylation (%) 64,7 55,2
Overall survival (median: days (months)) 480 (15) 429 (14)
Progression-free survival (median: days
(months))
186 (6) 180 (5)
Survival after relapse (median: days (months)) 266 (9) 187 (6)
Complete resection at 1st surgery (%) 32,4 31
Radiotherapy at 1st diagnosis (%) 100 100
TMZ at 1st diagnosis (%) 14,7 17,2
Therapies other than BCNU at recurrence
(re-resection, re-irradiation, TMZ, CCNU,
thalidomide)
38,2 24,1
BCNU cycles (% of patients) N/A
- ≤6 88,2
- 7–10 5,9
- not determinable 5,9
N/A: not applicable
Fig. 2 Kaplan-Meier plots depicting survival after relapse of 63 patients treated with (“BCNU”) or without (“control”) BCNU after recurrent GBM.
Note that the association of BCNU treatment with an improved survival after relapse (a) was even more pronounced in patients with other
therapies than BCNU at tumor recurrence (“with” compared to “w/o” (without); b) as well as in patients with hypermethylated MGMT promoter
(c) while patients with unmethylated MGMT promoter did not seem to benefit from BCNU treatment (d)
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of patients receiving salvage therapies; p = 0.28) in the
BCNU group, multiple regression suggested BCNU-
based chemotherapy to be an independent prognostic
factor of prolonged survival after relapse (HR = 0.48;
p = 0.02).
These data are supported by a phase II trial conducted
by Brandes et al. [23] that treated 40 patients suffering
from recurrent GBM with BCNU given for up to 6 cycles
alone or in combination with re-resection. PFS-6 was
17.5 % and median OS from the onset of chemotherapy
was 7.53 months (equivalent to the terminus “survival
after relapse” in our study). Response to chemotherapy
was the only independent prognostic factor for PFS-6,
whereas KPS and previous histology of low-grade glioma
were the only independent prognostic factors for OS.
Our survival data are also comparable to those of other
phase II trials for recurrent GBM analyzing the effect of
BCNU in combination with other drugs (Table 5). In a
retrospective analysis of 35 mostly TMZ-pre-treated pa-
tients with recurrent GBM, Reithmeier et al. reported
slightly inferior survival data with PFS-6 of 13 %, PFS of
11 weeks and OS of 22 weeks after BCNU treatment
[28]. Noteworthy, these patients received a mean of
1.8 cycles BCNU only, pre-treatment at tumor relapse
was very heterogeneous and commencement of BCNU
therapy varied between the 1st and 4th relapse. Interest-
ingly, in a multivariate analysis no influence of TMZ
pre-treatment on patient outcome was found, tempting
the authors to question the concern that pre-treatment
with another alkylating agent such as TMZ might not
only increase toxicity but also reduce the efficacy of
nitrosoureas due to an acquired drug resistance. How-
ever, like in the majority of studies, the significance of
this finding is impaired by the lack of the MGMT pro-
moter methylation status. In a meta-analysis of 504 co-
horts with 24 193 patients Wolff and co-workers
reported ACNU- and CCNU-containing regimens to be
superior to BCNU in terms of OS, even though the dif-
ferent nitrosourea-treated cohorts were not comparable
due to variations in treatment regimens and histology
[15]. BCNU was predominantly applied as monotherapy
for recurrent GBM whereas ACNU and CCNU were ad-
ministered in combination with other drugs in newly di-
agnosed high-grade gliomas [15]. Beside, in a single
center study of TMZ-pretreated patients with recurrent
GBM, ACNU alone or in combination with other drugs
Table 4 Prognostic factors of survival after tumor relapse (“survival after relapse”) based on a multiple Cox regression model (n = 63
patients)
Variable Hazard ratioa 95 % CI p-value
Age at 1st diagnosis per year 1.03 1.00–1.05 0.04
EOR CR vs. PR 0.76 0.41–1.40 0.64
TMZ at 1st diagnosis yes vs. no 0.32 0.15–0.71 0.005
Therapies other than BCNU at tumor recurrence yes vs. no 0.56 0.30–1.02 0.06
MGMT promoter methylation yes vs. no 0.89 0.51–1.53 0.66
BCNU yes vs. no 0.48 0.26–0.89 0.02
aA hazard ratio <1 (>1) indicates an effect in favor of the first (second) group
CI confidence interval, EOR extent of resection, CR complete resection, PR partial resection/biopsy
Table 5 Synopsis of selected phase II chemotherapy trials performed for recurrent GBM
Reference Intervention Pts. (n) chemo-naïve (%) PFS6 mo (%) PFS (weeks)
Brandes (2004) [23] BCNU ± re-resection 40 100 17.5 13.3
Fine (2003) [25] BCNU + thalidomide 38 50 27 14.9
Prados (2004) [26] BCNU + TMZ (single dose) 38 89.5 21 11
Brandes (2004) [24] BCNU + irinotecan 42 0 30.3 17
Yung (2000) [46] TMZ (5/28) vs. procarbazine 112 35 21 vs. 8 12.4
Brada (2001) [47] TMZ (5/28) 128 29 18 8
Brandes (2002) [48] TMZ (5/28) 42 0 24 11.7
Chang (2004) [49] TMZ (5/28) 142 56 18 10
Wick (2007) [50] TMZ (7/14) 64 36 43.8 24
Perry (2010) [51] TMZ (continuous) 91 NR 23.9 7–15
Kappelle (2001) [52] PCV 63 68.2 29 13
Wong (1999) [53] historical controls 225 NR 15 9
ND not determined, NR not reported
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failed to induce a significant stabilization of disease,
however at the expense of 50 % high-grade hematotoxi-
city [18]. Hence a potential advantage of one nitrosourea
derivate over another still needs to be determined, par-
ticularly in a homogeneously pre-treated patient sample.
It has to be noted, however, that recent meta-analyses of
predominantly phase II trials for the use of TMZ or the
antiangiogenic agent bevacizumab in patients with re-
current GBM reported PFS-6 rates superior to those of
the previously discussed nitrosourea studies [37, 38].
The observational, retrospective design of our survival
analysis confers some disadvantages, including a poten-
tial selection bias by comparing two groups of patients
compiled on the basis of availability of outcome data
and tumor tissue, uncontrolled for known and suspected
prognostic factors. Accordingly, median age was non-
significantly lower and treatment intensity at tumor re-
lapse was non-significantly higher in the BCNU group,
but we used multiple regression analysis to take into
account this imbalance. Although the sample size was
relatively small to simultaneously assess six prognostic
factors, BCNU treatment consistently proved to be an
independent prognostic factor for a prolonged survival
after relapse. The present study also has some strengths.
We analyzed a homogeneously pre-treated, mostly
chemotherapy-naïve cohort of patients with uniform
histology (recurrent GBM). Importantly, only patients
with IDH wildtype GBM were included, eliminating the
unique molecular and prognostic phenotype variability
related to IDH mutant GBM [29]. In contrast to other
studies, MGMT promoter methylation status, which is
predictive for the response of GBM to alkylating drugs
like TMZ and nitrosoureas [31, 39, 40], was included in
the multivariate model, showing an even pronounced
survival benefit for MGMT-hypermethylated, BCNU-
treated patients. Moreover, the EOR at 1st surgery was
objectively quantified by routine post-operative MRI
scans and was included in the multivariate model as
well. This is of importance since complete resection of
newly diagnosed GBM has been shown to be a positive
prognostic factor for a prolonged survival [2, 41–44].
Given the poor prognosis of high-grade gliomas, espe-
cially after tumor relapse, quality of life experienced by
these patients is an important issue. However, many
second-line chemotherapy regimens are highly toxic. In
our analysis of chemotherapy-related side effects, BCNU
was well tolerated. Interestingly, side effects were not
equally observed among tumor grades, with WHO grade
IV patients experiencing least and WHO grade II pa-
tients experiencing most frequently side effects. It is
worth noting that treatment intensity (radiotherapy,
chemotherapy) prior to BCNU-based chemotherapy in-
creased with WHO grade (data not shown). The retro-
spective nature of our study does not allow an
explanation, but this finding may be due to the consider-
ably extended life span of WHO grade II patients com-
pared to higher-grade glioma patients with an increasing
likelihood of observing side effects. Out of 163 patients
treated with BCNU for recurrent glioma WHO grade II
to IV, 54 % experienced mostly mild chemotherapy-
related side effects, predominantly due to myelosuppres-
sion. Severe side effects CTCAE III/IV were observed in
9 % of all patients including hematotoxicity, thrombo-
embolism, intracranial hemorrhage and injection site re-
action requiring surgical intervention. Only one patient
presented with the most dreaded side effect of BCNU
administration, a clinically apparent pulmonary fibrosis
CTCAE IV requiring temporary mechanical ventilation.
These data are comparable or even superior to other
multimodal treatment regimens in chemotherapy-naïve
patients with newly diagnosed GBM (Table 6). The
EORTC 22981/26981 trial [1] reported hematotoxicity
CTCAE III/IV in 16 % of patients undergoing postopera-
tive radio-chemotherapy with TMZ. As for nitrosourea-
Table 6 BCNU-related side effects - Comparison of own results to the literature
Reference Cytotoxic agent Hematotoxicity Pulmonary SE CTH-related
deaths (%)CTCAE III/IV (%) CTCAE I - IV (%)
Stupp (2005) [1] TMZ (+RT) 16 - -
Buckner (2006) [27] BCNU (+ RT) L 28 10 -
T 44
Weller (2003) [45] BCNU (+WBRT) - 12 4
Weller (2003) [45] ACNU/VM26 (+RT) 36,5 0,7 2,6
Brandes (2004) [23] BCNU L 8 ND
T 10 5
(WHO 3/4) (WHO 4)
own results BCNU L 1,8 0,6 0
T 3,6
SE side effects, CTCAE Common Toxicity Criteria, CTH chemotherapy, L leukopenia, T thrombocytopenia, RT radiotherapy, WBRT whole brain radiotherapy
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based regimens, Buckner et al. observed leucopenia and
thrombocytopenia CTCAE III/IV in 28 % and 44 % of
patients treated with BCNU ± radiotherapy [27], and the
NOA-01 trial reported hematotoxicity CTCAE III/IV in
36.5 % of patients exposed to ACNU/VM 26 in combin-
ation with radiotherapy [45]. In contrast, we observed
severe leucopenia and thrombocytopenia CTCAE III/IV
in 1.8 and 3.6 % of patients only. These data are in line
with the phase II trial by Brandes et al. in which WHO
grade 3/4 leucopenia and thrombocytopenia were
observed in 8 % and 10 % of cycles, respectively [23].
However, the authors reported a high incidence of pul-
monary (WHO grade 4: 5 % of patients) and hepatic
(WHO grade 2/3: 10 % of patients) toxicity, leading
them to the conclusion that even though patient out-
come was comparable to similar phase II trials with
TMZ as single agent, BCNU-associated toxicity was
more frequent and persistent. This study monitored pul-
monary function by diffusing capacity of the lung for
carbon monoxide. In contrast, the NCCTG/SOG trial
conducted by Buckner et al. made use of clinical exam-
ination and chest X-rays every other month and re-
ported adverse pulmonary events not further specified in
10 % of patients [27]. Finally, in the NOA-01 trial pul-
monary function was monitored merely by clinical
examination and patient’s history, detecting pulmonary
fibrosis in 0.7 % of patients [45]. Thus, studies analyzing
pulmonary toxicity of nitrosourea-based chemotherapy,
especially with a focus on pulmonary fibrosis, are diffi-
cult to compare due to heterogeneous monitoring tech-
niques of pulmonary function. In our analysis of side
effects, we screened medical records of a large, predom-
inantly chemotherapy-naïve patient sample for reports
on clinical symptoms of pulmonary dysfunction; further-
more, routine chest X-rays every 3 months were part of
our in-house protocol for patients exposed to BCNU-
based chemotherapy. Therefore, even though our study
design was a retrospective one, pulmonary monitoring is
comparable to the one employed by Buckner et al. [27].
However, the incidence of pulmonary fibrosis detected
both clinically and radiographically was much lower
(0.6 %; 1 out of 163 patients) and is actually in the range
of ACNU-related pulmonary toxicity reported by Weller
et al. [45]. Our data suggest that a clinically apparent
pulmonary fibrosis caused by BCNU might be less fre-
quent than previously feared and that BCNU, in this re-
spect, is not inferior to other nitrosourea derivatives.
Nevertheless, a more sensitive monitoring instrument of
pulmonary function would be desirable in order to
strengthen this notion.
Conclusions
In our analysis of BCNU-based chemotherapy in pa-
tients with recurrent glioma, BCNU was well tolerated
and, in case of recurrent GBM, even conferred a signifi-
cant survival benefit. If these encouraging results hold
true in nowadays TMZ-pre-treated patients, still needs
to be determined. Since no standard therapy exists for
recurrent high-grade glioma and a survival benefit of
other nitrosoureas over BCNU has not been proven yet,
we propose to further evaluate its efficacy in future pro-
spective trials.
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